Research Analysts Set Expectations for Moderna, Inc.’s Q2 2024 Earnings (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) – Stock analysts at Zacks Research reduced their Q2 2024 earnings estimates for Moderna in a research report issued on Thursday, May 23rd. Zacks Research analyst S. Ganoria now forecasts that the company will post earnings of ($3.47) per share for the quarter, down from their prior estimate of ($3.37). The consensus estimate for Moderna’s current full-year earnings is ($7.47) per share. Zacks Research also issued estimates for Moderna’s Q3 2024 earnings at ($1.57) EPS, Q4 2024 earnings at $0.56 EPS, FY2024 earnings at ($7.55) EPS, Q1 2025 earnings at ($3.24) EPS, Q2 2025 earnings at ($3.37) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at $1.78 EPS, FY2025 earnings at ($5.38) EPS, Q1 2026 earnings at ($3.07) EPS and FY2026 earnings at ($1.92) EPS.

Other equities research analysts also recently issued reports about the company. Evercore ISI began coverage on Moderna in a research note on Tuesday, May 14th. They set an “in-line” rating and a $120.00 price target for the company. Royal Bank of Canada raised their price objective on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Oppenheimer boosted their target price on shares of Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. HSBC restated a “reduce” rating and set a $86.00 price target (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Finally, UBS Group increased their target price on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $126.46.

Moderna Price Performance

MRNA opened at $166.61 on Monday. The stock has a fifty day moving average price of $115.62 and a 200 day moving average price of $100.78. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. Moderna has a 1 year low of $62.55 and a 1 year high of $170.47. The stock has a market cap of $63.85 billion, a price-to-earnings ratio of -10.63 and a beta of 1.57.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. During the same quarter last year, the business posted $0.19 EPS. The company’s revenue for the quarter was down 91.0% on a year-over-year basis.

Hedge Funds Weigh In On Moderna

A number of hedge funds have recently made changes to their positions in the business. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Moderna during the 4th quarter valued at about $27,000. Arlington Trust Co LLC lifted its stake in Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares during the period. Cedar Wealth Management LLC boosted its holdings in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new stake in shares of Moderna in the 1st quarter valued at approximately $32,000. Finally, Rise Advisors LLC raised its holdings in shares of Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Transactions at Moderna

In other Moderna news, President Stephen Hoge sold 255 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the sale, the president now directly owns 1,486,508 shares of the company’s stock, valued at approximately $179,808,007.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Stephen Hoge sold 255 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the transaction, the president now directly owns 1,486,508 shares of the company’s stock, valued at $179,808,007.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 185,209 shares of company stock worth $20,951,971. Insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.